 A bruising FDA meeting for Cytokinetics was actually a blessing in disguise, an analyst said Wednesday as CYTK stock surged. The post Why Cytokinetics Is Soaring After A Bruising FDA Meeting For Its Heart Drug appeared first on Investors Business Daily. 